Pooled 48-week results from two Phase II studies show sustained antiviral responses and a favorable safety profile of AHB-137 in HBeAg-negative chronic hepatitis B patients on NA therapy.

SAN FRANCISCO , Nov. 8, 2025 /PRNewswire/ -- AusperBio Therapeutics, Inc. and Ausper Biopharma Co., Ltd. (together AusperBio ), a clinical-stage biotechnology company, today announced that 48-week data from its two ongoing Phase II studies of AHB-137 were presented in a late-breaking poster session at the American Association for the Study of Liver Diseases ( AASLD ) The Liver Meeting® 2025, held November 7–11 in Washington D.C., USA.

The presentation featured pooled 48-week data from two multicenter, randomized Phase II studies (Phase IIa, NCT06115993 ; Phase IIb, NCT06550128 ) in HBeA

See Full Page